Inter J Geriatric Sieg: Prospective Cohort Study: Dementia Diagnosis Has New Biomarkers

!---- introduction: Alzheimer's has always been one of the unsolvable problems in the medical communitythe World Health Organization estimates that the total number of people with dementia will reach 82 million by 2030 and 152 million by 2050there are about 9 million people with Alzheimer's disease in China, and it is expected to exceed 40 million by 2050however, the cause of the disease is still unclear, medical researchers in the UK and Australia have identified a new biomarker that could support the search for new ways to prevent and treat dementiathe progression of Alzheimer's disease has the hallmarks of amyloid plaque lesions, the death of sexual neurons, and the abnormal build-up of tau proteins in neuronsand a growing number of studies have shown that the incidence of Alzheimer's disease is associated with risk factors for cardiovascular diseasenitric oxide (NO) has a definite interbody action in the pathogenesis of cardiovascular disease, while asymmetrical dimethyl argininine (ADMA) is an endogenous inhibitor of nitric oxide (NOS)in epidemiological studies, alymmetric dimethylargine (ADMA) can be used as a blood marker associated with atherosclerosis and cardiovascular diseaseresearchers recently found that asymmetrical dimethylargine (ADMA) can be another biomarker for Alzheimer's disease to predict the development of the diseasethestudy, co-led by the University of Oxford, the University of Aberdeen and flinders University of Australia, and published in the International Journal of Geriatric Psychiatry, entitled "Circulating asymmetric dimethylargine and cognitive decline: A 4-year follow-up study of the 193 In this innovative study, conducted in collaboration with Flinders University and the University of Aberdeen, researchers investigated the role of asymmetrical dimethylargine (ADMA) in the study of cognitive changes in the elderly in a human aging queue (Aberdeen Birth Queue 1936)researchers assessed the cognitive abilities of older people using the standard Raven Progressive Matrix (RPM) tests from 2000 to 2001, 2002 to 2003 and 2003-2004unlike other human ageing research teams, these aberdeen-born elderly people, born in 1936, also took child intelligence tests at the age of 11, a key predictor of their intelligence and healthstudies showed that most older people showed slow cognitive decline over a four-year follow-up periodand their plasma ADMA concentrations were negatively linearly associated with cognitive abilities"In the first longitudinal study, a decrease in ADMA levels measured in 2000 (the age of 63) was associated with a decrease in cognitive ability assessment four years later," said Professor Arduino Mangoni, director of the Department of Clinical Pharmacology at Flinders University,where ADMA concentrations were negatively linear lyson edited by cognitive abilitiestherefore, the results of this study suggest that ADMA is an easy-to-measure indicator of atherosclerosis and cardiovascular disease risk, may also be an early indicator of cognitive decline in old age, and may even be an early marker of Alzheimer's diseaseUK researcher Dr Deborah Malden said: 'We should be cautious about the results of the new study and further extensive investigation is needed.' "If we can repeat this experiment in a large-scale cohort study, we're going to get more information, which could involve thousands of people, and maybe a gene MR (Mendel randomization) study," she said"If the initial findings are confirmed in large-scale studies, the researchers hope the findings could pave the way for a population with a higher risk of dementia,"important, the concentration of ADMA can be regulated through pharmacological interventions, which may also provide the basis for future treatment strategies to reduce ADMA levels to slow down the cognitive decline in old age